23andMe Research Institute
Genomic engine designed for scale, patient understanding, and clinical action
Platform · Cloud SaaSCompany source
Company profile
About 23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
Company description 23andMe official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at 23andMe?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- 55+ common chronic diseases and high-impact conditions
- Alzheimer's disease
- asthma
- cancer
- diabetes
- heart health
- lupus
- mental health
- Parkinson's disease
Who it serves
- clinical practices
- consumers
- health systems
- healthcare professionals
- research institutions
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Geographic context
MarketsUnited States · worldwide
Company sourceOfficial website
Company milestones
Platform expansion
Launch of 23andMe Total Health platform with exome sequencing and biannual blood testing, 23andMe Research Institute for healthcare partnerships, TIME Best Inventions 2025 recognition
Partnerships
Recorded partners
- Alnylam Pharmaceuticals
- Biogen
- Broad Institute of MIT and Harvard
- Genentech
- GlaxoSmithKline (GSK)
- Lupus Research Institute
- MRC Epidemiology Unit at Cambridge University
- National Parkinson Foundation
- P&G Beauty
- Parkinson's Institute and Clinical Center
- Pfizer
- Stanford University
- The Michael J. Fox Foundation
- University of Chicago
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
23andMe+ Premium
Membership fueled by discovery, sharpened by time with 100+ genetic insights and action tools
Platform · Cloud SaaSCompany source
23andMe+ Total Health
Next gen longevity platform with exome sequencing, biannual blood testing and genetics-informed clinical care
Platform · HybridCompany source
Ancestry Service
The most comprehensive ancestry breakdown on the market
Service · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.The pharmacogenomics journal · Aug 5, 2026
Prediction of alcohol consumption: The role of genetics, impulsivity, and sensation seeking from adolescence to adulthood.Drug and alcohol dependence · Jul 29, 2026
Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson's disease.NPJ Parkinson's disease · Jul 14, 2026
Molecular genetic influences on sustained attention and executive processes and their links with psychopathology in the AFFECT study.Molecular psychiatry · Jul 7, 2026
Just-in-time education to prepare clinicians for genomics.Trends in genetics : TIG · Jul 1, 2026
Early-Onset Vitreous and Cardiac Amyloidosis With TTR Trp61Leu.JACC. Case reports · Jun 17, 2026
Clinical validation
Clinical-trial records
Slow-SPEED: Slowing Parkinson's Early Through Exercise DosageNCT06993142 · Sponsor · RECRUITING
Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-NetherlandsNCT06193252 · Sponsor · RECRUITING
Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 CarriersNCT07646054 · Sponsor · NOT YET RECRUITING
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsNCT04446351 · Sponsor · ACTIVE NOT RECRUITING
23andMe IPF Research StudyNCT05028894 · Sponsor · COMPLETED
Study of 23ME-01473 in Patients With Advanced Solid MalignanciesNCT06290388 · Sponsor · TERMINATED
Regulatory
Regulatory records
23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary ThrombophiliaDEN160026 · De Novo · Apr 6, 2017
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
1 in 11 patients received medically actionable hereditary disease sequencing result
directly changing care plan
82% of patients with highly actionable risks had no prior awareness
before testing
88% adherence to medical recommendations
given to address genetic results
Clinical Practice (unnamed)
Comprehensive genomic risk assessment and patient screening
1 in 11 patients received medically actionable hereditary disease sequencing result directly changing care plan; 82% of patients with highly actionable risks had no prior awareness; 88% adherence to medical recommendations
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from 23andMe
Recent articles published on 23andMe's official website.
Alzheimer’s Awareness Month: The Science Is Moving Fast
Read on 23andMeYou Asked Which Parent You Got It From. Now You Can Find Out.
Read on 23andMeNew Historical Matches Could Connect You to Britain’s Beachy Head Woman
Read on 23andMeA New Study Shows How Focus and Executive Function Are Genetically Different
Read on 23andMeHow Fast Are You Really Aging?
Read on 23andMe07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.